SCHEDULE 13G/A: EcoR1 Capital Discloses 8.1% Stake in Allovir, Inc. Following Reverse Stock Split
Beneficial Ownership Disclosure
EcoR1 Capital, LLC and its affiliates have disclosed a beneficial ownership of 8.1% in Allovir, Inc.'s common stock as of December 31, 2024, following a recent 1-for-23 reverse stock split.
Summary
- EcoR1 Capital, LLC, along with its control person Oleg Nodelman, beneficially owns 408,688 shares of Allovir, Inc. common stock.
- This ownership represents an 8.1% stake in Allovir, Inc.'s common stock.
- EcoR1 Capital Fund Qualified, L.P., an affiliate, beneficially owns 385,705 shares, representing a 7.7% stake.
- The percentage ownership is calculated based on 5,041,932 shares of Common Stock outstanding as of January 30, 2025.
- This calculation follows a 1-for-23 reverse stock split of Allovir, Inc.'s Common Stock.
- The shares are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects. It is a neutral regulatory filing.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership by an institutional investor in a publicly traded company, common in the biotechnology sector where specialized funds often take significant positions. It reflects a passive investment stance by EcoR1 Capital in Allovir, Inc., a company that recently underwent a reverse stock split, a common corporate action often undertaken by companies to increase their share price and meet listing requirements.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership and the impact of the recent reverse stock split on share count and percentage ownership.
Key Dates
| Date | Description |
|---|---|
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership snapshot). |
| 2025-01-30 | Date on which 5,041,932 shares of Common Stock were outstanding, used for percentage calculation, following the reverse split. |
| 2025-02-10 | Date of Proxy Statement filed by the Issuer reporting the outstanding shares post-reverse split. |
| 2025-02-14 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Allovir Inc., EcoR1 Capital, Oleg Nodelman, Beneficial Ownership, Schedule 13G, Common Stock, Reverse Stock Split, Biotechnology, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.